Methyl90
Senior Member
- Messages
- 282
Hello everyone, I was wondering if inhibiting the 4 pyruvate kinase complexes could facilitate PDH? Has anyone tried calcium pyruvate or ethyl pyruvate? ALA also appears to inhibit all 4 complexes.
Has anyone tried calcium pyruvate or ethyl pyruvate?
Have you tried out ALA R? High Doses of Thiamine HCL?
It's certainly possible, though I think I'm differentiating between chronic fatigue, and full-blown me/cfs. When the results were taken, I felt a bit fatigued and perpetually hung-over, but definitely no PEM, or any other of the cardinal symptoms of ME.You say you had this done 1 month before ME onset, yet your onset wasn't viral (sudden) but perhaps more gradual? So I'm guessing you weren't feeling well to have the OATS test done? So its possible you did have ME at the time you did the test or you were developing ME.
Btw, did the FMTs help in any way?I have RALA every day, have done for 4 years now. Its one of the more effective supplements. I used to use high doses of thiamine and/or benfotiamine but didn't really help any. There isn't much I haven't tried, even tried 3 FMT's!
@Levant What have you done to address your oxalate problem, which can drive a lot of other problems? It can cause oxidative stress, sap your mineral co-factorsV vitamins, and antioxidants?
Dealing with the oxalates with a low oxalate diet and supplements like garcinia cambogia (for the hydroxycitrate) or calcium, magnesium, or potassium citrate and B6 is the best treatment, while replenishing minerals and antioxidants is helpful.
The lowoxalate.info website and Trying Low Oxalates FB group are both helpful resources - the latter has the most accurate list of oxalate foods.
(spacing added for readability)Proal and Van Elzakker 2021 said:The Warburg effect refers to a metabolic state in which cells preferentially use aerobic glycolysis rather than oxidative phosphorylation to generate ATP and macromolecules.
A number of chronic inflammatory conditions are characterized by host cells that adopt a sustained, pathological Warburg-like metabolism. In cancer, previously healthy cells shift into a Warburg state centered on rapid energy production and increased cell proliferation that drives tumor formation. Macrophage in atherosclerotic plaque and in sarcoidosis granuloma can also harbor a Warburg-like phenotype that promotes an inflammatory milieu.
The question of why host cells in patients with cancer and other chronic inflammatory conditions adapt a pathological Warburg-like metabolism is a matter of debate. This review/hypothesis piece explores how intracellular infection can contribute to this Warburg metabolism or related pathological metabolic states. We detail molecular mechanisms by which viral, bacterial, and protozoan intracellular pathogens can induce, or contribute to, a Warburg-like metabolism in infected host cells in order to meet their own replication and nutritional needs.
We also discuss how host defense towards infection may impact cellular metabolic changes. We then provide examples of how many of these same intracellular pathogens have been identified in tumors, atherosclerotic lesions, granuloma, and other tissues containing cells with a Warburg or altered metabolism. Last, we examine further trends associated with infection and host cell metabolism, including how pathogen-driven hijacking of host cell lipid metabolism can support viral, bacterial, and parasite survival and replication.
Why do some ME/CFS patients benefit from treatment with sodium dichloroacetate, but others do not?
Author links open overlay panelFrankComhaire
Show more
Outline
Share
Cite
https://doi.org/10.1016/j.mehy.2018.08.014Get rights and content
Abstract
Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is an enigmatic disease the pathogenesis of which remains elusive. Pragmatic proof-of-principle of the hypothetical mechanisms causing the clinical symptoms has been delivered, but it is hard to explain why some patients do respond favourably to treatment with sodium dichloroacetate (DCA), which enhances the activity of the mitochondrial enzyme pyruvate dehydrogenase, but other patients experience no benefit from this substance.
In a prospective trial including 35 ME/CFS patients, logistic regression analysis with stepwise elimination has identified 6 pre-treatment characteristics allowing for the differentiation between responders (n = 13) and non-reponders (n = 22) with high accuracy (P < 0.0001; area under the ROC-curve = 0.92). A formula was derived generating the probability of belonging to the group of responders. This finding may assist in selecting ME/CFS patients suitable for treatment with DCA, but requires further studies as to the predictive capacity of the derived formula.
Yeah it kinda relates to dichloroacetate. Dichloroacetate is about activating more PDH1 while i think about deactivating PDH2.